Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under ticker DECA, is a clinical-stage biopharmaceutical company that became publicly listed through its business combination with Decathlon Acquisition Corp., a blank-check vehicle that completed its initial public offering in 2021. The combined company is focused on developing novel pain-management therapeutics, with its lead program targeting lumbosacral radiculopathy. Semnur filed its annual report on Form 10-K with the Securities and Exchange Commission on April 2, 2025, covering fiscal year 2024 operations as a post-combination public company in the pharmaceutical sector. For full deal history, filing data, and sponsor details on DECA, sign up for a SpacDesk account at spacdesk.com.